Prexasertib - Eli Lilly

Drug Profile

Prexasertib - Eli Lilly

Alternative Names: Captisol® enabled prexasertib; LY 2606368; LY 2606368 MsOH H2O

Latest Information Update: 04 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Array BioPharma; Eli Lilly
  • Developer Dana-Farber Cancer Institute; Eli Lilly; National Cancer Institute (USA)
  • Class Antineoplastics; Nitriles; Pyrazines; Pyrazoles; Small molecules
  • Mechanism of Action Checkpoint kinase 1 inhibitors; Checkpoint kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours
  • Phase I Acute myeloid leukaemia; Colorectal cancer; Head and neck cancer; Myelodysplastic syndromes; Non-small cell lung cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Jun 2018 Efficacy, pharmacokinetics and adverse events data from a phase Ib trial in Solid tumours presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 16 May 2018 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease) in USA (IV) (NCT03495323)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top